The Future of Regulatory Affairs in Pharma and Life Sciences: From Technical Function to Strategic Leadership
7 min read
What will distinguish exceptional Regulatory Affairs leaders over the next five years?
In a recent conversation with Stefan König, CEO of Merz Therapeutics, one message emerged clearly:
The role of Regulatory Affairs is evolving far beyond its traditional remit. Today’s leaders are expected not only to navigate complex regulatory landscapes, but also to shape development strategy, influence business outcomes, and drive enterprise-wide collaboration. As drug development becomes increasingly complex and global, Regulatory Affairs is moving closer to the center of strategic decision-making.
The Moment Regulatory Affairs Starts to Matter Has Moved Upstream
One of the most significant shifts is the timing of Regulatory Affairs involvement.
Rather than entering the process shortly before registration, Regulatory teams are now engaged during preclinical development and early clinical phases. Scientific advice discussions with regulators, endpoint selection, and development strategy are increasingly shaped through early collaboration between Regulatory Affairs, Development, and Market Access.
As König explains:
Together with Market Access, Regulatory Affairs is today involved much earlier in the process. These discussions determine whether a product is approvable and will be competitive in the market. At its best, Regulatory Affairs does more than navigate approval pathways. It helps identify development strategies that accelerate innovation and bring meaningful new therapies to patients faster.
This early involvement creates a unique opportunity for Regulatory Affairs leaders to influence the trajectory of development programs long before pivotal studies begin.
The New Regulatory Affairs Leader
This shift has several implications:
- Deeper scientific expertise is required to excel as a Regulatory Affairs executive, particularly in early clinical development. Regulatory work has become more scientific in nature.
- Stronger cross-functional leadership is essential. Leaders must operate effectively in matrix organizations, influence across functions, and balance scientific, regulatory, and commercial priorities.
As Stefan König puts it:
The role is no longer about narrow technical expertise but about strategic, cross-functional thinking and broader leadership.
The ability to connect stakeholders, challenge assumptions, and align diverse interests is becoming just as important as regulatory knowledge itself.
Where Regulatory Affairs Creates Business Value
Perhaps the greatest business impact comes from decisions around clinical endpoints.
As König notes:
Clinical endpoint decisions have become one of the most powerful levers in pharmaceutical development, shaping not only regulatory approval, but also reimbursement, physician adoption, patient access, and long-term commercial success. Success requires balancing regulatory approval requirements, commercial relevance, and market access considerations. All three elements need to come together.
The Leadership Gap: Strategic Foresight
When asked about the biggest talent gaps in Regulatory Affairs, König identified one capability above all: strategic foresight - the ability to anticipate what regulators will require in the future.
Too often, the focus remains on the present rather than shaping future regulatory frameworks, particularly in mid-sized pharmaceutical companies.
Large pharma organizations tend to perform better in this area due to greater resources. Mid-sized companies are often absorbed by day-to-day execution and lack the capacity for longer-term (3–5 year) strategic thinking.
The most effective leaders, however, will not simply react to change - they will help shape it.
What Companies Should Be Looking For
When discussing succession planning and hiring, König highlighted three non-negotiable qualities for a future Head of Regulatory Affairs:
- Global regulatory experience, including exposure to major health authorities such as the FDA and EMA
- Proven success in influencing complex matrix organizations without formal authority, aligning scientific, commercial, medical, and development stakeholders around critical decisions
- A strategic perspective on how the regulatory landscape is evolving - and how to actively shape that future
Taken together, these capabilities describe a leader who operates beyond functional boundaries and contributes directly to enterprise value creation.
Looking Ahead
The future Head of Regulatory Affairs will be more than a regulatory expert. They will be a strategist, collaborator, influencer, and architect of future regulatory pathways – helping shape how innovation reaches patients while creating sustainable value for the business. Those who combine scientific credibility with enterprise leadership will be best positioned to shape the next generation of innovation in life sciences.
At the same time, advances in artificial intelligence, real-world evidence, and data analytics are transforming how companies generate evidence and engage with regulators, creating new opportunities for Regulatory Affairs to drive strategic advantage.
Perspectives from Executive Search
From an executive search perspective, Regulatory Affairs leadership roles remain among the most challenging in the pharmaceutical industry to fill.
As Veronika Ulbort notes:
Organizations are seeking leaders who combine deep regulatory expertise, global experience, strong matrix leadership capability, and credibility with regulators, executive teams, and boards. Few candidates bring all of these dimensions together – and they are increasingly in demand.
At the same time, career decisions at this level are rarely driven by compensation alone.
As Nikolai Albrecht observes:
The most sought-after leaders are typically already well positioned in strong organizations and tend to move only for exceptional opportunities. These decisions are driven by scope and impact rather than title or remuneration.
In short, as demand continues to exceed supply, it is essential for companies to clearly articulate a differentiated value proposition that is focused on the ambition, real influence and scope of the opportunity being offered.